Cell-culture brain models called organoids can be used to study far more advanced stages of neurodevelopment than researchers once imagined, according to new research.

A team funded by the National Institutes of Health (NIH) reports that organoids were sustained for almost six years—far longer than previous efforts. The findings, detailed in a recent paper published in Nature, showed that a developmental clock similar to the one governing real brains also appears to govern organoid maturation.

The work could significantly expand researchers’ ability to study later stages of human brain development and neurological conditions that emerge over longer periods.

Organoids Explained

Organoids have been a major and growing tool in neurological research. They consist of small cell cultures arranged into 3D models of human brain tissue. Typically, these have been limited to only basic reconstructions, yet the new work significantly advances their modeling capabilities by expressing much later-stage brain development attributes.

Significantly, the NIH-funded team says that the work could pave the way for previously impossible neurodevelopmental studies.’

Organoids occupy a crucial space in research because they can be used to study processes that are difficult to investigate directly at the cellular level in living human brains. However, their typically limited lifespans have largely restricted neuroscientists to studying earlier stages of development. Another challenge has been the high variability between batches of cells, which the researchers addressed by producing cerebral cortex organoids with more consistent cellular compositions.

Consistency was not the team’s only advancement. In laboratory experiments, the organoids also survived and continued developing for much longer periods.

Longer Lifespans

The team tracked biological age and gene expression by observing chemical changes to the genome and examining cellular characteristics down to the level of individual cells. Many key developmental milestones in the organoids, including the emergence and maturation of neurons, occurred on timelines resembling those seen during normal human brain development. The biological clocks in the organoids closely corresponded with the molecular and chronological ages observed in humans.

Although these organoids developed outside the human body, their maturation proceeded at a similarly slow pace.

Notably, neurons in the organoids continued establishing connections and displaying electrical activity for years. The researchers attributed their ability to maintain this activity in part to a specialized fluid designed to support long-term neuronal function.

“The brain doesn’t develop in a vacuum. It’s an organ of incredible complexity that interacts with so many other systems. It was not a given at all that our simplified model would match natural development in this many ways,” said co-first author Irene Faravelli, M.D., Ph.D.

Organoid Neurons

During their experiments, the team transplanted neurons between organoids of different ages to determine how their new environments would affect their development. Remarkably, transplanted neurons largely retained developmental characteristics associated with the organoids from which they originated rather than resetting their developmental trajectories to match their younger surroundings.

“I like to think of this as a sort of ‘warping of developmental time’ indicating that the organoid cells record and recall the time they have already spent in culture. This suggests their development is driven by a cell-intrinsic clock, reflecting mechanisms of endogenous human brain development,” said co-author Paola Arlotta, Ph.D, of Harvard University.

Having significantly expanded researchers’ understanding of what organoids can model, the team now hopes to increase their complexity further, potentially allowing scientists to investigate additional developmental processes and test interventions.

“There is still much to learn about how the embryo naturally builds a progressively more complex and mature brain,” Arlotta concluded. “Applying these lessons to organoids will allow us to model unexplored events of human brain maturation that occur after birth.”

The paper, “Human Brain Organoids Record the Passage of Time over Multiple Years,” appeared in Nature on August 19, 2026.

Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org.

A new study has brought scientists closer to observing how inflammation during pregnancy may alter the earliest stages of human brain development. Using three-dimensional tissue models made from human fetal brain samples, researchers modeled maternal immune activation and identified the signaling molecule interleukin-17A, or IL-17A, as a major driver of abnormal cortical development. The findings, published in Nature Neuroscience, offer a human-based experimental system for investigating how immune signals outside the brain can influence the formation of neural circuits before birth.

Maternal immune activation refers to the biological response triggered when a pregnant individual experiences infection or significant inflammation. Epidemiological studies have associated certain prenatal inflammatory exposures with an increased likelihood of neurodevelopmental conditions, including autism spectrum disorder, schizophrenia, and intellectual disability. Yet the mechanisms behind these associations have remained difficult to study. Animal models have provided important clues, but differences between species can limit their ability to reproduce the timing, cellular organization, and molecular environment of the developing human cortex.

The researchers addressed this challenge with “brain cerebroids,” three-dimensional, ex vivo models that preserve features of developing human fetal brain tissue. Unlike simplified cultures composed of a single cell type, these structures retain a more complex arrangement of neural progenitors, immature neurons, and supporting cells. Their three-dimensional architecture allows cells to communicate and organize in ways that more closely resemble the fetal cortex, including the production and movement of neurons that ultimately establish the layered structure of the brain’s outer region.

To recreate aspects of maternal immune activation, the team exposed the fetal brain cerebroids to inflammatory conditions associated with immune signaling during pregnancy. The central focus was IL-17A, a cytokine produced primarily by activated immune cells, particularly a subset of T cells known as T helper 17 cells. Cytokines are small signaling proteins that coordinate immune responses, but they can also affect tissues beyond the immune system. In the developing brain, inappropriate or excessive exposure to such signals may influence cell proliferation, migration, differentiation, and the formation of connections between neurons.

The study found that IL-17A exposure was linked to disruptions in cortical development within the human cerebroids. These effects are described as “IL-17A-driven,” indicating that the cytokine was not merely associated with the developmental changes but played a functionally important role in producing them. The disturbances affected the organization and behavior of developing neural cells, processes that are essential for building the cortex. During normal development, neural progenitor cells generate new neurons in tightly regulated sequences, while young neurons migrate to their appropriate positions. Interference with either process can alter the structure and connectivity of later-forming brain tissue.

The results are especially significant because they were observed in human fetal brain material rather than inferred only from animal studies. Previous research in mice has implicated maternal immune activation and IL-17A in changes to cortical organization and behavior in offspring. However, the human cerebroid model provides an opportunity to examine whether similar immune mechanisms operate in human tissue, where the timing of neurogenesis, cell-type composition, and cortical architecture differ from those of rodents. The approach may also help reveal human-specific responses that conventional laboratory animals cannot capture.

The findings do not mean that IL-17A exposure during pregnancy inevitably causes a neurodevelopmental condition, nor do they establish that prenatal inflammation is a single explanation for such conditions. Brain development is shaped by a combination of genetic factors, immune signals, environmental influences, and developmental timing. The experiments also took place in an ex vivo model, outside the full physiological environment of a living pregnancy. Cerebroids cannot reproduce the placenta, maternal circulation, hormonal changes, or the complete immune system, all of which influence how inflammatory signals reach the fetus and how long they remain active.

Nevertheless, the model could become a powerful platform for testing mechanisms and potential interventions. Researchers may use it to determine how IL-17A changes gene activity in neural progenitors, whether it alters communication between neurons and glial cells, and which molecular pathways make some developing cells more vulnerable than others. Because the tissue is human and three-dimensional, it may also support studies of patient-specific genetic risk, allowing investigators to compare how different backgrounds respond to the same inflammatory signal.

The work also highlights a broader shift in neuroscience toward experimental systems that combine human tissue with controlled laboratory manipulation. Understanding prenatal inflammation is difficult in clinical studies because immune exposure cannot be ethically assigned or precisely timed in pregnant people. Brain cerebroids offer a way to isolate individual components of that complex biology while preserving more of the developing tissue’s natural organization than conventional two-dimensional cell cultures. As these models improve, they may help distinguish temporary developmental changes from persistent alterations in cortical circuitry and identify when immune signaling is most consequential.

By showing that IL-17A can disrupt human cortical development in a three-dimensional ex vivo system, the study gives researchers a clearer biological target in the search for links between prenatal inflammation and later neurodevelopment. Its most immediate contribution is not a new diagnosis or treatment, but a more precise experimental framework: one that connects maternal immune signaling to cellular events in the developing human cortex. That connection could guide future work on prevention, therapeutic timing, and the complex origins of developmental differences long before the first symptoms become visible.

Subject of Research: Maternal immune activation and IL-17A-driven disruption of human fetal cortical development in 3D ex vivo brain cerebroids.

Article Title: Modeling maternal immune activation in 3D ex vivo human fetal brain cerebroids reveals IL-17A-driven disruption of cortical development.

Article References: Assir, M.Z.K., Yanakiev, M., Gim, D.H. et al. Modeling maternal immune activation in 3D ex vivo human fetal brain cerebroids reveals IL-17A-driven disruption of cortical development. Nature Neuroscience (2026). https://doi.org/10.1038/s41593-026-02400-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02400-2

Keywords: maternal immune activation, IL-17A, fetal brain development, cortical development, brain cerebroids, neurodevelopment, prenatal inflammation, human brain models, cytokines, neuroscience

Gut microbes are increasingly being viewed as hidden regulators of brain health, and a new study in Translational Psychiatry adds fuel to that idea by tracing a biochemical pipeline from the gut to stress-related mental disorders. The research, led by Yuan, Qin, Wu and colleagues, reports that metabolites produced—or shaped—by gut microbiota can influence developmental trajectories associated with anxiety- and stress-linked pathology.

Rather than focusing solely on which bacterial species are present, the team examined functional metabolic output. Using integrative approaches that combine microbiome profiling with metabolomic measurements, the researchers identified gut-derived compounds whose levels tracked with downstream markers relevant to stress vulnerability. The results suggest that microbial metabolism may act as an early biochemical “switch,” tuning how stress signals are processed later.

A key finding is that these microbial metabolites do not merely correlate with symptoms; they appear to modulate mechanisms tied to disorder emergence. The study proposes that certain metabolite patterns can reshape host signaling pathways implicated in stress reactivity, including processes that affect neurodevelopment and the maturation of stress-response circuits.

The work also highlights how microbial communities can influence the chemical environment of the gut, altering metabolite availability and thereby changing what reaches the systemic circulation. Once in contact with host tissues, these metabolites may interact with receptors or influence cellular pathways involved in inflammation control and neuronal function—two domains frequently linked to stress-related psychiatric conditions.

Importantly, the paper frames gut–brain communication as a developmentally time-sensitive phenomenon. By emphasizing “development of stress-related mental disorders,” the authors argue that microbial metabolite exposure during critical windows could bias the risk landscape long before clinical symptoms emerge.

Methodologically, the study leverages translational reasoning, connecting microbial metabolites to mechanistic readouts rather than stopping at taxonomic associations. This strategy strengthens the causal plausibility of a microbiota-driven metabolic model and provides candidate compounds that could be targeted in future interventions.

From a public-health perspective, the findings support the growing concept that dietary patterns, probiotics, or precision microbiome therapies might be designed to adjust metabolite production. Such interventions could potentially recalibrate stress susceptibility by shifting the gut’s chemical outputs toward more protective profiles.

As the field advances, the study’s DOI—10.1038/s41398-026-04154-8—marks another step toward metabolite-centered strategies for mental health, where gut chemistry becomes a lever for preventing stress-driven disorders.

Subject of Research: Gut microbiota-driven metabolites and stress-related mental disorders
Article Title: Gut microbiota-driven metabolites modulate the development of stress-related mental disorders.
Article References: Yuan, M., Qin, F., Wu, L. et al. (2026). Translational Psychiatry. https://doi.org/10.1038/s41398-026-04154-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04154-8

A groundbreaking study from Mass General Brigham Neuroscience Institute has uncovered crucial genetic underpinnings of congenital cerebral ventriculomegaly (CCV), a disorder characterized by the abnormal swelling of fluid-filled brain ventricles in fetuses. Frequently observed alongside autism spectrum disorder and other neurodevelopmental conditions, CCV has long been a clinical challenge due to its complex origins and unpredictable outcomes.

By analyzing genetic data from approximately 2,700 children diagnosed with CCV and their parents, researchers identified rare, deleterious mutations affecting genes integral to early brain development. These genes regulate the growth and organization of neural cells critical to forming the cerebral cortex—the brain’s center for cognition, memory, and language. Notably, mouse models in which these genes were silenced exhibited enlarged ventricles, linking genetic abnormalities directly to functional and structural brain defects.

This pioneering work shifts the medical understanding of CCV from purely a cerebrospinal fluid circulation disorder to one deeply rooted in developmental brain pathology. It suggests that the ventricular system’s dysfunction reflects a broader impairment in neural circuit formation and brain architecture, potentially explaining why many infants with CCV experience developmental delays and an increased risk of autism.

The implications of these findings are profound. Prenatal neuroimaging combined with targeted genetic screening could enable earlier diagnosis of at-risk fetuses, opening the door to timely interventions before the onset of symptoms. Current neurosurgical treatments, while often lifesaving, do not consistently improve neurological outcomes and expose patients to risks such as infections and lifelong shunt dependency.

Kristopher T. Kahle, MD, PhD, Chief of Pediatric Neurosurgery at Mass General Brigham and senior author of the study, emphasizes the potential of genomic testing to revolutionize patient care. He anticipates that genetic profiling could refine clinical decisions, distinguishing patients who would benefit from surgery from those better served by alternative therapies.

The study’s integration of human genetic analysis with animal modeling represents a paradigm shift, enhancing our grasp of how genetic mutations disrupt cerebrospinal fluid dynamics and cerebral cortex development simultaneously. This dual perspective is poised to stimulate further research aimed at therapeutic innovations targeting the molecular roots of CCV.

Ultimately, this research underscores a critical nexus between developmental neurogenetics and pediatric neurosurgery, offering hope for improved diagnostic precision and personalized treatment strategies. With continued advancements, clinicians may one day prevent or mitigate the neurodevelopmental disabilities often associated with ventriculomegaly, improving quality of life for countless affected children.

Subject of Research: Human tissue samples
Article Title: Developmental genetic determinants of the human cerebrospinal fluid-ventricular system
News Publication Date: —
Web References: https://doi.org/10.1126/scitranslmed.aec4386
References: Allington G et al. Science Translational Medicine. DOI: 10.1126/scitranslmed.aec4386
Keywords: Hydrocephalus, Congenital cerebral ventriculomegaly, Neurodevelopmental disorders, Autism spectrum disorder, Pediatric neurosurgery, Genomic testing

In the rapidly advancing field of assisted reproductive technologies (ART), subtle biochemical cues during treatment cycles can have profound and lasting impacts on offspring health. A groundbreaking study by Jiang, Wei, Liu, and colleagues, set to appear in Nature Communications in 2026, reveals intricate links between human chorionic gonadotropin (hCG) exposure on the trigger day of ART protocols and enduring epigenetic modifications that influence neurodevelopmental trajectories in children conceived via these methods. This research shines a spotlight on the complex interplay between hormonal interventions during ART and the epigenetic landscape shaping long-term neurodevelopmental outcomes.

At the core of this investigation lies hCG, a glycoprotein hormone traditionally recognized for its critical role in early pregnancy maintenance. It is clinically administered as a trigger to induce final oocyte maturation and subsequent ovulation in ART cycles. Despite its widespread use, the broader biological consequences of hCG administration timing and dosage, particularly regarding the epigenome of resulting embryos and offspring, remain poorly understood. Jiang and colleagues address this knowledge gap by systematically evaluating how hCG exposure on trigger day affects DNA methylation patterns—a key epigenetic mechanism regulating gene expression—in offspring conceived via ART.

Utilizing a large cohort of ART offspring and sophisticated epigenomic profiling techniques, the researchers uncovered that variations in trigger-day hCG levels corresponded to distinct DNA methylation signatures detectable in peripheral tissues of the children years post-birth. These methylation changes were not random but localized to genes with established roles in neurodevelopment and synaptic function. Notably, altered methylation was observed in loci involved in neuronal proliferation, differentiation, and synaptic plasticity, processes fundamental to cognitive development and neurological health.

The implications of these findings are considerable given the rising prevalence of ART-conceived individuals globally. Epigenetic modifications such as DNA methylation are dynamic yet heritable through cell division, and perturbations during critical windows of embryonic development can have cascading effects on gene regulation. Jiang et al.’s data suggest that the timing and hormonal milieu created by hCG administration on trigger day may inadvertently shape the epigenetic program of the embryo with consequences extending into postnatal brain development.

To unravel the potential neurodevelopmental consequences, the team correlated their epigenetic data with standardized neuropsychological assessments performed on the ART offspring. They reported significant associations between specific methylation patterns and measures of cognitive function, executive processing, and social behavior, domains frequently implicated in neurodevelopmental disorders. This links the biochemical intervention in ART directly to behavioral phenotypes observed in the children, underscoring the functional relevance of epigenetic imprinting driven by hCG exposure.

Mechanistically, the study posits that hCG triggers a cascade of intracellular signaling events including modulation of DNA methyltransferase (DNMT) activity and chromatin remodelers during oocyte maturation and early embryo development. These processes may alter the establishment or maintenance of methylation marks at neurodevelopmentally critical genes. Interestingly, variations in the hCG dose and timing created distinct epigenomic landscapes, emphasizing the fine balance required in ART hormone protocols to avoid unintended epigenetic dysregulation.

This research not only advances understanding of ART-associated neurodevelopmental risks but also offers actionable insights for clinical practice. Optimizing hCG administration parameters could mitigate adverse epigenetic and developmental outcomes, enhancing the safety profile of ART. The notion that a single hormonal manipulation at a specific time point can induce persistent epigenomic and neurodevelopmental alterations demands a reevaluation of ART protocols incorporating epigenetic endpoints.

The findings may also have broader implications beyond ART, revealing fundamental principles of how transient hormonal milieus during early development can imprint long-lasting changes on gene regulation and phenotype. This could inform developmental biology, neuroepigenetics, and endocrine research, potentially identifying biomarkers predictive of neurodevelopmental risk across diverse prenatal exposures.

Furthermore, the study leverages cutting-edge epigenomic technologies such as whole-genome bisulfite sequencing and single-cell methylation analysis, coupled with rigorous neurobehavioral phenotyping in a longitudinal cohort framework. This integrative, multi-omics approach sets a new standard for assessing the safety and long-term effects of reproductive interventions, blending molecular precision with clinical relevance.

Ethically, these insights prompt a dialogue about the need for comprehensive monitoring of ART offspring, integrating epigenetic screening and neurodevelopmental surveillance to detect and potentially intervene in early deviations. The epigenetic alterations detected by Jiang et al. are reversible in principle, raising the prospect of targeted epigenetic therapies or nutritional interventions to restore typical developmental trajectories.

Moreover, the study encourages further exploration into paternal contributions and environmental factors interacting with trigger-day hCG effects, recognizing that ART outcomes emerge from a complex interplay of genetics, epigenetics, and external exposures. Identifying modifiers of hCG-induced epigenetic programming could refine personalized ART approaches tailored to individual risk profiles.

Overall, this landmark research by Jiang and colleagues opens a new frontier in reproductive medicine, illustrating that the endocrinology of ART cycles extends beyond immediate gamete maturation to sculpt the epigenomic and neurodevelopmental fate of future generations. It reinforces the imperative for precision medicine in reproductive technologies and highlights the power of epigenetics in mediating early-life environmental influences on human development.

As ART continues to bring hope to millions struggling with infertility, understanding and controlling the subtle molecular ripples of treatment interventions like hCG administration becomes paramount. Jiang et al.’s study sets a vital precedent, demonstrating that optimizing hormone triggers is not merely a matter of improving pregnancy rates but safeguarding the neurological health and well-being of ART-conceived individuals throughout their lives.

Subject of Research: Human chorionic gonadotropin (hCG) effects on DNA methylation and neurodevelopment in offspring conceived via assisted reproductive technologies (ART).

Article Title: Trigger-day hCG effects on DNA methylation and neurodevelopment in ART offspring.

Article References:
Jiang, Y., Wei, X., Liu, X. et al. Trigger-day hCG effects on DNA methylation and neurodevelopment in ART offspring. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74712-7

Image Credits: AI Generated

Emerging insights into autism spectrum disorder (ASD) have been propelled forward by an innovative study examining cortical development dynamics using multiple mouse models. This work delves deeply into the transcriptional landscapes shaped by mutations implicated in ASD, revealing a complex interplay of stage-specific and genotype-specific molecular signatures. Employing cutting-edge network colocalization analyses and protein–protein interaction mapping, the study illuminates how biological processes converge and diverge during neurodevelopment in mutant genotypes.

Fundamentally, the research builds upon gene set enrichment analysis (GSEA), which previously highlighted overlapping pathways across various ASD-related mutations. The researchers expanded on this by applying network colocalization analysis to protein interaction networks, allowing functionally related proteins to be grouped into clusters through sophisticated averaging of random walks. This methodological advancement enables a nuanced assessment of expression changes aggregated at the systems-level rather than focusing solely on individual genes.

At the heart of their findings is the identification of distinct yet overlapping patterns of molecular dysregulation during critical developmental stages, particularly embryonic day 14.5 (E14.5), postnatal day 4 (P4), and postnatal day 14 (P14). At E14.5, the study reveals that mutations such as those in HnrnpU and Kdm6b robustly influence pathways tied to the actin cytoskeleton, cell proliferation, and division within excitatory neurons. Notably, these effects also extend, to a lesser degree, to Cul3 mutants, aligning with earlier evidence suggesting these genes’ involvement in neurodevelopmental regulation.

Delving deeper, the analysis highlights a provocative role of WNT signaling, especially pronounced in HnrnpU and Kdm6b variants. WNT pathways are critical for neural patterning and synaptogenesis, and their disruption could underpin some ASD phenotypes. This novel perspective accentuates the shared mechanistic underpinnings of ASD mutations converging on fundamental developmental pathways, stressing the importance of timing within neurodevelopmental trajectories.

Postnatally, at P4 and P14, the transcriptional alterations shift noticeably towards synaptic functions, ion transport, and metabolic processes—markers of neuronal specialization and circuit maturation. The data demonstrate how the influence of mutations evolves alongside neural differentiation and maturation. Intriguingly, Kmt5b mutants exhibited an inverse pattern at P4, suggesting either a compensatory or opposing regulatory role within the shared pathways affected across mutants. This counterintuitive finding raises the possibility of complex feedback or adaptive mechanisms operating in ASD-linked genetic variants.

By P14, metabolic processes prominently emerge in the affected molecular networks, especially in Bckdk, HnrnpU, and Trip12 mutants, indicating that energy metabolism perturbations may be integral to ASD pathogenesis. These results underscore the temporal dynamics of how genetic mutations impinge upon neurodevelopment, transitioning from early cytoskeletal and proliferative effects to later synaptic and metabolic modulation.

The study also innovatively explores how differentially expressed genes from each genotype localize within the interactome network and assesses similarity across developmental stages and mutations. This reveals a compelling developmental-stage-dependent pattern where transcriptional signatures cluster more closely within each stage but become more genetically distinct by P14. Such divergence suggests that while ASD mutations initially impact common biological processes, their influence fragments into distinct genotype-specific programs as development proceeds.

These findings have broad implications for understanding ASD heterogeneity and the challenges of developing universal therapeutic interventions. The discovery of both shared and unique pathway disruptions at different developmental times suggests treatment strategies may need to be tailored to both genotype and developmental timing to maximize efficacy. Moreover, the role of metabolic dysregulation invites further exploration into metabolic interventions or dietary modulation as adjunctive strategies.

Critically, the network colocalization analysis used represents a powerful approach to dissecting complex genetic disorders. By moving beyond simple gene expression differences and integrating system-level interactions, researchers can better capture the multifaceted nature of neurodevelopmental perturbations characteristic of ASD. This systems biology approach is likely to prove invaluable in future studies dissecting the molecular bases of brain disorders.

The comprehensive nature of this study, which integrates multiple ASD-relevant mouse models, enables the identification of convergent and divergent mechanisms with precision. It highlights how individual genes implicated in autism can distinctly alter transcriptional landscapes depending on context, highlighting the multifactorial dimension of ASD. Additionally, it underscores that the timing of gene dysregulation is paramount, with early embryonic disruptions cascading into diverse neurodevelopmental consequences.

In sum, this landmark investigation offers a rich, dynamic map of the molecular trajectories altered by ASD mutations across cortical development. Its integration of genomic, proteomic, and network analyses provides a blueprint for future research aimed at unraveling the complexity of neurodevelopmental disorders. By elucidating how multiple risk genes influence overlapping yet unique biological processes during critical developmental windows, the study charts a path toward precision medicine in autism spectrum disorder.

As the field progresses, leveraging such multi-dimensional analytical frameworks will be essential for translating genetic discoveries into mechanistic insights and targeted therapies. This work also highlights the ongoing need to examine neurodevelopment through temporal and molecular lenses simultaneously, enriching our understanding of how genetic diversity shapes brain development and function. Ultimately, investigations like these nurture hope for deciphering the intricate biology underlying ASD and devising effective interventions tailored to individual developmental trajectories.

Subject of Research: Cortical development dynamics and molecular mechanisms in autism spectrum disorder mouse models.

Article Title: Cortical development dynamics across autism spectrum disorder mouse models.

Article References:
Schwarz, L.A., Dotter, C.P., Isaev, S. et al. Cortical development dynamics across autism spectrum disorder mouse models. Nature (2026). https://doi.org/10.1038/s41586-026-10679-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10679-1